<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303068</url>
  </required_header>
  <id_info>
    <org_study_id>HRRC, 12-521</org_study_id>
    <nct_id>NCT01303068</nct_id>
  </id_info>
  <brief_title>Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF</brief_title>
  <official_title>Detection of Pseudomonas. Aeruginosa in the Airways of Patients With Cystic Fibrosis Using of Aerosolized 13C-urea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if inhaled urea can be used to detect the presence&#xD;
      of Pseudomonas Aeruginosa in the lungs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Escalation study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Objective is to Assess the Safety of 13C Urea Administered by Inhalation.</measure>
    <time_frame>6 hours</time_frame>
    <description>The primary endpoint is the safety of inhaled 13C urea assessed by adverse events including pulmonary findings and changes from baseline in physical examination findings, pulse oximetry results, pulmonary function test results, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Objective is to Assess the Kinetics of 13C Carbon Dioxide Production by Measuring the Isotopic Ratio of 13C to 12C in Exhaled Carbon Dioxide.</measure>
    <time_frame>5 minutes post inhalation</time_frame>
    <description>Secondary endpoints are the isotopic ratios of 13C to 12C in exhaled carbon dioxide measured with the POCone detector (Meretek Diagnostics Group of Otsuka America Pharmaceutical, Rockville, MD) at 5, 10, and 15 minutes after study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients, 13C urea breath test kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF patients with Pseudomonas infection tested with 13C urea breath test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls, 13C urea breath test kit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects using 13C urea breath test kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>13C urea breath test Kit</intervention_name>
    <description>20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
    <arm_group_label>CF patients, 13C urea breath test kit</arm_group_label>
    <arm_group_label>Healthy controls, 13C urea breath test kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CF aged 18 years and above colonized with P. aeruginosa&#xD;
&#xD;
          -  Normal subjects ages 18 and above without CF or p. aeruginosa&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  for patients and volunteers will include the presence of asthma, allergic rhinitis,&#xD;
             pregnancy, a history of gastric or duodenal ulcer, smoking, and a baseline FEV1 less&#xD;
             than 60% of predicted normal value and a pulmonary exacerbation within the last 2&#xD;
             weeks as defined by use of systemic antibiotic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hengameh Raissy, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <disposition_first_submitted>December 10, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 13, 2016</disposition_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Hengameh Raissy, Pharm.D.</investigator_full_name>
    <investigator_title>Research Associate Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF Patients, 13C Urea Breath Test Kit</title>
          <description>CF patients with Pseudomonas infection tested with 13C urea breath test&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects Using 13C Urea Breath Test Kit</title>
          <description>Healthy subjects using 13C urea breath test kit&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF Patients, 13C Urea Breath Test Kit</title>
          <description>CF patients with Pseudomonas infection tested with 13C urea breath test&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls, 13C Urea Breath Test Kit</title>
          <description>Healthy subjects using 13C urea breath test kit&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="B2" value="32" lower_limit="24" upper_limit="41"/>
                    <measurement group_id="B3" value="29" lower_limit="23" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Objective is to Assess the Safety of 13C Urea Administered by Inhalation.</title>
        <description>The primary endpoint is the safety of inhaled 13C urea assessed by adverse events including pulmonary findings and changes from baseline in physical examination findings, pulse oximetry results, pulmonary function test results, and vital signs.</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF Patients, 13C Urea Breath Test Kit</title>
            <description>CF patients with Pseudomonas infection tested with 13C urea breath test&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects Using 13C Urea Breath Test Kit</title>
            <description>Healthy subjects using 13C urea breath test kit&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Objective is to Assess the Safety of 13C Urea Administered by Inhalation.</title>
          <description>The primary endpoint is the safety of inhaled 13C urea assessed by adverse events including pulmonary findings and changes from baseline in physical examination findings, pulse oximetry results, pulmonary function test results, and vital signs.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Objective is to Assess the Kinetics of 13C Carbon Dioxide Production by Measuring the Isotopic Ratio of 13C to 12C in Exhaled Carbon Dioxide.</title>
        <description>Secondary endpoints are the isotopic ratios of 13C to 12C in exhaled carbon dioxide measured with the POCone detector (Meretek Diagnostics Group of Otsuka America Pharmaceutical, Rockville, MD) at 5, 10, and 15 minutes after study drug administration.</description>
        <time_frame>5 minutes post inhalation</time_frame>
        <population>CF patients with infection has a higher 13C urea in their exhaled breath.</population>
        <group_list>
          <group group_id="O1">
            <title>CF Patients, 13C Urea Breath Test Kit</title>
            <description>CF patients with Pseudomonas infection tested with 13C urea breath test&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects Using 13C Urea Breath Test Kit</title>
            <description>Healthy subjects using 13C urea breath test kit&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
          </group>
        </group_list>
        <measure>
          <title>The Secondary Objective is to Assess the Kinetics of 13C Carbon Dioxide Production by Measuring the Isotopic Ratio of 13C to 12C in Exhaled Carbon Dioxide.</title>
          <description>Secondary endpoints are the isotopic ratios of 13C to 12C in exhaled carbon dioxide measured with the POCone detector (Meretek Diagnostics Group of Otsuka America Pharmaceutical, Rockville, MD) at 5, 10, and 15 minutes after study drug administration.</description>
          <population>CF patients with infection has a higher 13C urea in their exhaled breath.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2.2" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6.2" upper_limit="14.5"/>
                    <measurement group_id="O2" value="2.13" lower_limit="0.1" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CF Patients, 13C Urea Breath Test Kit</title>
          <description>CF patients with Pseudomonas infection tested with 13C urea breath test&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
        <group group_id="E2">
          <title>Healthy Subjects Using 13C Urea Breath Test Kit</title>
          <description>Healthy subjects using 13C urea breath test kit&#xD;
13C urea breath test Kit: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hengameh Raissy</name_or_title>
      <organization>University of New Mexico</organization>
      <phone>5052725484</phone>
      <email>hraissy@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

